"{\n \"business_address\": \"50 NORTHERN AVENUE, BOSTON, MA 02210\", \n \"business_phone_no\": \"6173416393\", \n \"ceo\": \"Jeffrey M. Leiden\", \n \"cik\": \"0000875320\", \n \"company_url\": \"www.vrtx.com\", \n \"employees\": 2150, \n \"entity_legal_form\": \"INCORPORATED\", \n \"entity_status\": null, \n \"hq_address1\": null, \n \"hq_address2\": null, \n \"hq_address_city\": null, \n \"hq_address_postal_code\": null, \n \"hq_country\": \"United States of America\", \n \"hq_state\": \"Massachusetts\", \n \"inc_country\": \"United States of America\", \n \"inc_state\": \"Massachusetts\", \n \"industry_category\": \"Drugs\", \n \"industry_group\": \"Biotechnology\", \n \"latest_filing_date\": \"2017-07-28\", \n \"legal_name\": \"VERTEX PHARMACEUTICALS INC / MA\", \n \"lei\": \"54930015RAQRRZ5ZGJ91\", \n \"long_description\": \"Vertex Pharmaceuticals Incorporated discovers, develops, manufactures, and commercializes medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene. The company also develops Tezacaftor (VX-661), a corrector compound that is in a Phase III development program in combination with ivacaftor in multiple CF patients; VX-152 and VX-440 that are CFTR corrector compounds in Phase II clinical trials, as well as VX-659 and VX-445 that are CFTR corrector compounds in Phase I clinical trials; and VX-371, an investigational epithelial sodium channel, which is in a Phase II development program. In addition, it engages in the research and mid-and early-stage development programs in the areas of oncology, pain, and neurology. The company sells its products primarily to specialty pharmacy providers and wholesalers in North America, as well as government-owned and supported customers internationally. Vertex Pharmaceuticals Incorporated has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; Parion Sciences, Inc.; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Merck KGaA; and Janssen Pharmaceuticals, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.\", \n \"mailing_address\": \"50 NORTHERN AVENUE, BOSTON, MA 02210\", \n \"name\": \"Vertex Pharmaceuticals Inc\", \n \"sector\": \"Healthcare\", \n \"securities\": [\n  {\n   \"composite_figi\": \"BBG000C1S2X2\", \n   \"composite_figi_ticker\": \"VRTX:US\", \n   \"currency\": \"USD\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XNAS\", \n   \"figi\": \"BBG000C1SD31\", \n   \"figi_exch_cntry\": \"UW\", \n   \"figi_ticker\": \"VRTX:UW\", \n   \"figi_uniqueid\": \"EQ0010774100001000\", \n   \"last_crsp_adj_date\": \"2000-08-24\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XNAS\", \n   \"primary_listing\": true, \n   \"security_name\": \"VERTEX PHARMACEUTICALS INC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S68LJ8\", \n   \"stock_exchange\": \"NASDAQ\", \n   \"ticker\": \"VRTX\"\n  }, \n  {\n   \"composite_figi\": \"BBG004PVSS12\", \n   \"composite_figi_ticker\": \"VRTX*:MM\", \n   \"currency\": \"MXN\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XMEX\", \n   \"figi\": \"BBG004PVSS21\", \n   \"figi_exch_cntry\": \"MM\", \n   \"figi_ticker\": \"VRTX*:MM\", \n   \"figi_uniqueid\": \"EQ0000000030595954\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XMEX\", \n   \"primary_listing\": false, \n   \"security_name\": \"VERTEX PHARMACEUTICALS INC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S68LJ8\", \n   \"stock_exchange\": \"MEX\", \n   \"ticker\": \"VRTX\"\n  }, \n  {\n   \"composite_figi\": \"BBG00FZLQ7B5\", \n   \"composite_figi_ticker\": \"VRTXEUR:XA\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": true, \n   \"etf\": false, \n   \"exch_symbol\": \"^XWBO\", \n   \"figi\": \"BBG00FZLQ7V3\", \n   \"figi_exch_cntry\": \"XA\", \n   \"figi_ticker\": \"VRTXEUR:XA\", \n   \"figi_uniqueid\": \"EQ0000000054976415\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XWBO\", \n   \"primary_listing\": false, \n   \"security_name\": \"VERTEX PHARMACEUTICALS, INC.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S68LJ8\", \n   \"stock_exchange\": \"WBO\", \n   \"ticker\": \"VRTX\"\n  }, \n  {\n   \"composite_figi\": \"BBG000GNZR76\", \n   \"composite_figi_ticker\": \"VX1:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XFRA\", \n   \"figi\": \"BBG000GNZRT2\", \n   \"figi_exch_cntry\": \"GF\", \n   \"figi_ticker\": \"VX1:GF\", \n   \"figi_uniqueid\": \"EQ0010774100001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XFRA\", \n   \"primary_listing\": false, \n   \"security_name\": \"VERTEX PHARMACEUTICALS INC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S68LJ8\", \n   \"stock_exchange\": \"FRA\", \n   \"ticker\": \"VX1\"\n  }, \n  {\n   \"composite_figi\": \"BBG000GNZR76\", \n   \"composite_figi_ticker\": \"VX1:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XETR\", \n   \"figi\": \"BBG000GNZSN6\", \n   \"figi_exch_cntry\": \"GY\", \n   \"figi_ticker\": \"VX1:GY\", \n   \"figi_uniqueid\": \"EQ0010774100001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XETR\", \n   \"primary_listing\": false, \n   \"security_name\": \"VERTEX PHARMACEUTICALS, INC.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S68LJ8\", \n   \"stock_exchange\": \"XETRA\", \n   \"ticker\": \"VX1\"\n  }, \n  {\n   \"composite_figi\": \"BBG000GNZR76\", \n   \"composite_figi_ticker\": \"VX1:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XMUN\", \n   \"figi\": \"BBG000GNZTQ1\", \n   \"figi_exch_cntry\": \"GM\", \n   \"figi_ticker\": \"VX1:GM\", \n   \"figi_uniqueid\": \"EQ0010774100001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XMUN\", \n   \"primary_listing\": false, \n   \"security_name\": \"VERTEX PHARMACEUTICALS, INC.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S68LJ8\", \n   \"stock_exchange\": \"MUN\", \n   \"ticker\": \"VX1\"\n  }, \n  {\n   \"composite_figi\": \"BBG000GNZR76\", \n   \"composite_figi_ticker\": \"VX1:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XBER\", \n   \"figi\": \"BBG000GNZTZ1\", \n   \"figi_exch_cntry\": \"GB\", \n   \"figi_ticker\": \"VX1:GB\", \n   \"figi_uniqueid\": \"EQ0010774100001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XBER\", \n   \"primary_listing\": false, \n   \"security_name\": \"VERTEX PHARMACEUTICALS, INC.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S68LJ8\", \n   \"stock_exchange\": \"BER\", \n   \"ticker\": \"VX1\"\n  }, \n  {\n   \"composite_figi\": \"BBG000GNZR76\", \n   \"composite_figi_ticker\": \"VX1:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XDUS\", \n   \"figi\": \"BBG000GNZS56\", \n   \"figi_exch_cntry\": \"GD\", \n   \"figi_ticker\": \"VX1:GD\", \n   \"figi_uniqueid\": \"EQ0010774100001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XDUS\", \n   \"primary_listing\": false, \n   \"security_name\": \"VERTEX PHARMACEUTICALS, INC.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S68LJ8\", \n   \"stock_exchange\": \"DUS\", \n   \"ticker\": \"VX1\"\n  }, \n  {\n   \"composite_figi\": \"BBG006TLX2P0\", \n   \"composite_figi_ticker\": \"VRTX:SW\", \n   \"currency\": \"CHF\", \n   \"delisted_security\": true, \n   \"etf\": false, \n   \"exch_symbol\": \"^XSWX\", \n   \"figi\": \"BBG006TLX2R8\", \n   \"figi_exch_cntry\": \"SE\", \n   \"figi_ticker\": \"VRTX:SE\", \n   \"figi_uniqueid\": \"EQ0000000036706371\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XSWX\", \n   \"primary_listing\": false, \n   \"security_name\": \"VERTEX PHARMACEUTICALS INC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S68LJ8\", \n   \"stock_exchange\": \"SIX\", \n   \"ticker\": \"VRTX\"\n  }, \n  {\n   \"composite_figi\": \"BBG000GNZR76\", \n   \"composite_figi_ticker\": \"VX1:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XHAM\", \n   \"figi\": \"BBG000GNZWJ2\", \n   \"figi_exch_cntry\": \"GH\", \n   \"figi_ticker\": \"VX1:GH\", \n   \"figi_uniqueid\": \"EQ0010774100001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XHAM\", \n   \"primary_listing\": false, \n   \"security_name\": \"VERTEX PHARMACEUTICALS, INC.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S68LJ8\", \n   \"stock_exchange\": \"HAM\", \n   \"ticker\": \"VX1\"\n  }, \n  {\n   \"composite_figi\": \"BBG000GNZR76\", \n   \"composite_figi_ticker\": \"VX1:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XHAN\", \n   \"figi\": \"BBG000GNZR76\", \n   \"figi_exch_cntry\": \"GR\", \n   \"figi_ticker\": \"VX1:GR\", \n   \"figi_uniqueid\": \"EQ0010774100001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XHAN\", \n   \"primary_listing\": false, \n   \"security_name\": \"VERTEX PHARMACEUTICALS, INC.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S68LJ8\", \n   \"stock_exchange\": \"HAN\", \n   \"ticker\": \"VX1\"\n  }, \n  {\n   \"composite_figi\": \"BBG006TLX2P0\", \n   \"composite_figi_ticker\": \"VRTX:SW\", \n   \"currency\": \"CHF\", \n   \"delisted_security\": true, \n   \"etf\": false, \n   \"exch_symbol\": \"^XBRN\", \n   \"figi\": \"BBG006TLX2W2\", \n   \"figi_exch_cntry\": \"BW\", \n   \"figi_ticker\": \"VRTX:BW\", \n   \"figi_uniqueid\": \"EQ0000000036706371\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XBRN\", \n   \"primary_listing\": false, \n   \"security_name\": \"VERTEX PHARMACEUTICALS, INC.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S68LJ8\", \n   \"stock_exchange\": \"BRN\", \n   \"ticker\": \"US92532F1003\"\n  }, \n  {\n   \"composite_figi\": \"BBG000GNZR76\", \n   \"composite_figi_ticker\": \"VX1:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XSTU\", \n   \"figi\": \"BBG000GNZT36\", \n   \"figi_exch_cntry\": \"GS\", \n   \"figi_ticker\": \"VX1:GS\", \n   \"figi_uniqueid\": \"EQ0010774100001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XSTU\", \n   \"primary_listing\": false, \n   \"security_name\": \"VERTEX PHARMACEUTICALS, INC.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S68LJ8\", \n   \"stock_exchange\": \"STU\", \n   \"ticker\": \"VX1\"\n  }\n ], \n \"short_description\": \"Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis; infectious diseases, including viral infections, such as influenza, and bacterial infections; autoimmune diseases, such as rheumatoid arthritis; cancer, inflammatory bowel disease; and neurological disorders, including pain, Huntington's disease and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.\", \n \"sic\": 2834, \n \"standardized_active\": true, \n \"stock_exchange\": \"NasdaqGS\", \n \"template\": \"industrial\", \n \"ticker\": \"VRTX\"\n}"